---
title: "Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer: Specific populations questions"
description: "Specific populations questions on Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Can TRODELVY be used during pregnancy? How long is contraception needed after TRODELVY? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/specific-populations"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer: Specific populations questions

Manufacturer: Gilead Sciences, Inc.  
Prescribing information: [Trodelvy](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf)

## Specific populations

<a id="trodelvy-pregnancy-prevention"></a>

### Can TRODELVY be used during pregnancy?

> “Embryo-Fetal Toxicity: Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/reconstitution-and-administration#:~:text=Embryo%2DFetal%20Toxicity%3A%20Based%20on%20its,potential%20risk%20to%20a%20fetus.)

<a id="trodelvy-contraception"></a>

### How long is contraception needed after TRODELVY?

> “Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/reconstitution-and-administration#:~:text=Advise%20females%20of%20reproductive%20potential,3%20months%20after%20the%20last%20dose.)

## Related pages
- [Medical information: Trodelvy (sacituzumab govitecan-hziy): Metastatic triple-negative breast cancer](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/guidelines)
